2. MAPK/ERK Pathway Protein Tyrosine Kinase/RTK Anti-infection
  3. MAP3K VEGFR Antibiotic
  4. 5Z-7-Oxozeaenol

5Z-7-Oxozeaenol  (Synonyms: FR148083; L783279; LL-Z 1640-2)

Cat. No.: HY-12686 Purity: 99.30%
COA Handling Instructions

Molarity Calculator

5Z-7-Oxozeaenol is a natural anti-protozoan compound from fungal origin, acting as a potent irreversible and selective inhibitor of TAK1 and VEGF-R2, with IC50s of 8 nM and 52 nM, respectively.

For research use only. We do not sell to patients.

5Z-7-Oxozeaenol Chemical Structure

5Z-7-Oxozeaenol Chemical Structure

CAS No. : 253863-19-3

Size Price Stock Quantity
1 mg USD 250 In-stock
5 mg USD 950 In-stock
10 mg USD 1650 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 18 publication(s) in Google Scholar

5Z-7-Oxozeaenol Related Antibodies

Top Publications Citing Use of Products

    5Z-7-Oxozeaenol purchased from MedChemExpress. Usage Cited in: Neurosci Lett. 2022 Oct 18;136914.  [Abstract]

    5Z-7-oxozeaenol (10 nM) significantly inhibits LPS-induced high expression of NF-κB and TAK1 in microglial.

    View All MAP3K Isoform Specific Products:

    View All Isoforms
    MAP3K7/TAK1 MAP3K8 ASK2 MAP3K5/ASK1

    View All VEGFR Isoform Specific Products:

    View All Isoforms
    VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

    View All Antibiotic Isoform Specific Products:

    View All Isoforms
    Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    5Z-7-Oxozeaenol is a natural anti-protozoan compound from fungal origin, acting as a potent irreversible and selective inhibitor of TAK1 and VEGF-R2, with IC50s of 8 nM and 52 nM, respectively.

    IC50 & Target[1][2]

    TAK1

    8.1 nM (IC50)

    MEK1

    411 nM (IC50)

    VEGFR-2

    52 nM (IC50)

    VEGFR-3

    110 nM (IC50)

    FLT3

    170 nM (IC50)

    PDGFR-β

    340 nM (IC50)

    B-RAF VE

    6300 nM (IC50)

    SRC

    6600 nM (IC50)

    In Vitro

    5Z-7-Oxozeaenol is a potent irreversible and selective inhibitor of transforming growth factor (TGF)-β-activated kinase 1 (TAK1, IC50, 8.1 nM), less active on MEK1 (IC50, 411 nM). 5Z-7-Oxozeaenol prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase[1]. 5Z-7-Oxozeaenol is also an inhibitor of VEGF-R2, with an IC50 of 52 nM. 5Z-7-Oxozeaenol has inhibitory activity against VEGF-R3, FLT3, PDGFR-β, B-RAF VE and SRC, with IC50s of 110, 170, 340, 6300 and 6600 nM, respectively[2]. 5Z-7-Oxozeaenol inhibits JNK/p38 paythway, but it is not a direct inhibitor and is signal specific. 5Z-7-Oxozeaenol suppresses the PMA-induced AP-1 activity almost to the basal level in the KT cells, but has no effects on IL-1-induced NF-kB activity in the KK cells[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    5Z-7-Oxozeaenol Related Antibodies
    Molecular Weight

    362.37

    Formula

    C19H22O7
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C(O[C@@H](C)C/C=C\1)C2=C(O)C=C(OC)C=C2/C=C/C[C@H](O)[C@H](O)C1=O
    Structure Classification
    Initial Source

    Cochliobolus lunatus
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 30 mg/mL (82.79 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.7596 mL 13.7981 mL 27.5961 mL
    5 mM 0.5519 mL 2.7596 mL 5.5192 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (6.90 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (6.90 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.60%

    COA (256 KB) HNMR (289 KB) LCMS (268 KB)

    Handling Instructions (2659 KB)
    References
    Kinase Assay
    [1]

    For screening TAK1 inhibitors, insect expression vectors for TAK1 and TAB1 are co-infected into Sf9 cells. After 2 days of incubation, cell lysates are immunoprecipitated with anti-TAK1 antibody (M-17). The immunoprecipitates are incubated with various compounds (5Z-7-Oxozeaenol, etc.) and subsequently incubated with 2 μg of myelin basic protein and 10 μCi of [γ-32P]ATP (3,000 Ci/mmol) in 10 μL of the kinase buffer containing 10 mM HEPES (pH 7.4), 1 mM dithiothreitol, 5 mM MgCl2 at 30°C for 5 min. Samples are separated by 10% SDS-PAGE, and 32P incorporated into myelin basic protein is quantified with a bioimage analyzer. The catalytic activity of MEK1 is determined by activation of ERK2 to phosphorylate dure. The catalytic activity of MEKK1 is measured with 2 μg of myelin basic protein as a substrate in the kinase buffer. For subsequent kinase assays, immunoprecipitates are incubated with 5 μCi of [γ-32P]ATP (3,000 Ci/mmol) and 1 μg of bacterially expressed MKK6 or GST-IκBα-(1-72) in 10 μL of the kinase buffer at 25°C for 2 min. Samples are separated by 10% SDS-PAGE and visualized by autoradiography[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.7596 mL 13.7981 mL 27.5961 mL 68.9903 mL
    5 mM 0.5519 mL 2.7596 mL 5.5192 mL 13.7981 mL
    10 mM 0.2760 mL 1.3798 mL 2.7596 mL 6.8990 mL
    15 mM 0.1840 mL 0.9199 mL 1.8397 mL 4.5994 mL
    20 mM 0.1380 mL 0.6899 mL 1.3798 mL 3.4495 mL
    25 mM 0.1104 mL 0.5519 mL 1.1038 mL 2.7596 mL
    30 mM 0.0920 mL 0.4599 mL 0.9199 mL 2.2997 mL
    40 mM 0.0690 mL 0.3450 mL 0.6899 mL 1.7248 mL
    50 mM 0.0552 mL 0.2760 mL 0.5519 mL 1.3798 mL
    60 mM 0.0460 mL 0.2300 mL 0.4599 mL 1.1498 mL
    80 mM 0.0345 mL 0.1725 mL 0.3450 mL 0.8624 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    5Z-7-Oxozeaenol Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    5Z-7-Oxozeaenol253863-19-3FR148083 L783279 LL-Z 1640-2FR 148083FR-148083L783279L 783279L-783279MAP3KVEGFRAntibioticMAP kinase kinase kinase, MEKK, MAPKKKVascular endothelial growth factor receptorInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    5Z-7-Oxozeaenol
    Cat. No.:
    HY-12686
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.